These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 25885468

  • 1. A new relative tumor sizing method in epi-metaphyseal osteosarcoma.
    Kim SH, Shin KH, Park EH, Cho YJ, Park BK, Suh JS, Yang WI.
    BMC Cancer; 2015 Apr 15; 15():284. PubMed ID: 25885468
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N, Bieling P, Winkler P, Helmke K, Maas R, Baldini N, Heise U, Fuchs N, Winkler K.
    Klin Padiatr; 1993 Apr 15; 205(4):200-9. PubMed ID: 8377444
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tumor size and prognosis in aggressively treated osteosarcoma.
    Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K.
    J Clin Oncol; 1996 Mar 15; 14(3):848-58. PubMed ID: 8622033
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P.
    Cancer; 2006 Mar 01; 106(5):1154-61. PubMed ID: 16421923
    [Abstract] [Full Text] [Related]

  • 7. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH, Shin KH, Moon SH, Kong Y, Suh JS, Yang WI.
    J Surg Oncol; 2017 May 01; 115(6):752-759. PubMed ID: 28403564
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY.
    Oncology; 2011 May 01; 80(1-2):107-17. PubMed ID: 21677455
    [Abstract] [Full Text] [Related]

  • 10. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
    Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG.
    Ann Surg Oncol; 2008 Mar 01; 15(3):906-14. PubMed ID: 18163171
    [Abstract] [Full Text] [Related]

  • 11. [Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma].
    Ozger H, Eralp L, Atalar AC, Toker B, Ayan I, Kebudi R, Bağbek S, Başaran M, Ağaoğlu F, Dizdar Y, Bilgiç B.
    Acta Orthop Traumatol Turc; 2007 Mar 01; 41(3):211-9. PubMed ID: 17876121
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B, Pauli C, Botter SM, Bode-Lesniewska B, Fuchs B.
    BMC Cancer; 2015 May 09; 15():379. PubMed ID: 25956431
    [Abstract] [Full Text] [Related]

  • 13. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
    Bacci G, Longhi A, Cesari M, Versari M, Bertoni F.
    Cancer; 2006 Jun 15; 106(12):2701-6. PubMed ID: 16691623
    [Abstract] [Full Text] [Related]

  • 14. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
    Farfalli GL, Albergo JI, Lobos PA, Smith DE, Streitenberger PD, Pallotta Rodríguez MG, Aponte-Tinao LA.
    Medicina (B Aires); 2015 Jun 15; 75(2):87-90. PubMed ID: 25919869
    [Abstract] [Full Text] [Related]

  • 15. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N, Yamawaki S.
    J Orthop Sci; 2009 Jul 15; 14(4):397-404. PubMed ID: 19662473
    [Abstract] [Full Text] [Related]

  • 16. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG, Song WS, Cho WH, Kong CB, Cho SH.
    Clin Orthop Relat Res; 2014 Jun 15; 472(6):1911-20. PubMed ID: 24574120
    [Abstract] [Full Text] [Related]

  • 17. Post operative infection and increased survival in osteosarcoma patients: are they associated?
    Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A.
    Ann Surg Oncol; 2007 Oct 15; 14(10):2887-95. PubMed ID: 17653803
    [Abstract] [Full Text] [Related]

  • 18. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG, Kong CB, Cho WH, Song WS, Cho SH, Choi SW, Lee SY.
    J Surg Oncol; 2014 Mar 15; 109(3):275-9. PubMed ID: 24243222
    [Abstract] [Full Text] [Related]

  • 19. Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.
    Colding-Rasmussen T, Thorn AP, Horstmann P, Rechnitzer C, Hjalgrim LL, Krarup-Hansen A, Petersen MM.
    Acta Oncol; 2018 Mar 15; 57(3):420-425. PubMed ID: 28741397
    [Abstract] [Full Text] [Related]

  • 20. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
    Kimura H, Tsuchiya H, Shirai T, Nishida H, Hayashi K, Takeuchi A, Ohnari I, Tomita K.
    J Orthop Sci; 2009 Sep 15; 14(5):556-65. PubMed ID: 19802667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.